Andere Kunden interessierten sich auch für
![Interleukin-1¿ polymorphism and treatment response in HCV patients]( "Interleukin-1¿ polymorphism and treatment response in HCV patients")
Interleukin-1¿ polymorphism and treatment response in HCV patients44,99 €![HCV & Treatment "e;The Complete Story"e;]( "HCV & Treatment "e;The Complete Story"e;")
HCV & Treatment "e;The Complete Story"e;46,99 €![Preventive strategies for medical device-related nosocomial infections]( "Preventive strategies for medical device-related nosocomial infections")
Preventive strategies for medical device-related nosocomial infections44,99 €![Clinical, laboratory and histologic findings in chronic HCV patients]( "Clinical, laboratory and histologic findings in chronic HCV patients")
Clinical, laboratory and histologic findings in chronic HCV patients55,99 €![CD4+CD25+T cells in HCV patients & Prevalence of Bacterial infection]( "CD4+CD25+T cells in HCV patients & Prevalence of Bacterial infection")
CD4+CD25+T cells in HCV patients & Prevalence of Bacterial infection38,99 €![Seroprevalence of HBV/HCV-HIV Co-infections and outcome follow up of HAART in HIV Patients]( "Seroprevalence of HBV/HCV-HIV Co-infections and outcome follow up of HAART in HIV Patients")
Seroprevalence of HBV/HCV-HIV Co-infections and outcome follow up of HAART in HIV Patients26,99 €![Obstructive Sleep Apnea- Current Treatment Strategies]( "Obstructive Sleep Apnea- Current Treatment Strategies")
Obstructive Sleep Apnea- Current Treatment Strategies51,99 €
![HCV & Treatment "e;The Complete Story"e;](https://bilder.buecher.de/produkte/53/53585/53585361n.jpg "HCV & Treatment "e;The Complete Story"e;")
Currently approved antiviral therapy for HCV is PEG-IFN plus RBV for 48 weeks in genotypes 1 and 4, and for 24 weeks for genotypes 2 and 3. Acute HCV infection is usually asymptomatic and difficult in diagnosis. Occult HCV infection is a new entity that should be taken into account for the diagnosis of patients with elevated liver enzymes or liver disease of unknown aetiology. HCV infection causes many renal diseases especially membrano-proliferative glomerulonephritis type 1 which caused mostly by type II mixed cryoglobulinaemia. HCV infection especially genotype 3 carries higher risk of insulin resistance and hepatic steatosis which in turn help progression of liver diseases. HBV/HCV co-infection is not uncommon, especially within areas of high prevalence of HBV. Dual infections represent unique management challenges. This book is highlight the different treatment modalities of HCV patients in different medical conditions.